Acumen Pharmaceuticals, Inc. (ABOS) News

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q1 2023 Earnings Call Transcript

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q1 2023 Earnings Call Transcript May 14, 2023 Operator: Good day, and thank you for standing by. Welcome to the Acumen Pharma Q1 2023 Conference Call and Webcast. At this time all participants are in a listen-only mode. After the speaker’s presentation there’ll be a question-and-answer session. [Operator Instructions] Please be […]

Yahoo | May 16, 2023

Acumen Pharmaceuticals, Inc. (ABOS) Q1 2023 Earnings Call Transcript

Acumen Pharmaceuticals, Inc. (ABOS)

Q1 2023 Earnings Conference Call

May 09, 2023, 08:00 AM ET

Company Participants

Alex Braun - Head IR

Daniel O'Connell - President and CEO

Eric Siemers - Chief Medical Officer

Matt Zuga - CFO and Chief Business Officer

Conference Call Participants

Tom Shrader - BTIG

Judah Frommer - Credit Suisse

Charlie Yang - BofA

Presentation

Operator

Good day, and thank you for standing by. Welcome to the Acumen Pharma Q1 2023 Conference Call and Webcast. At this time all participants are in a listen-only mode. After the speaker’s presentation there’ll be a question-and-answer session. [Operator Instructions] Plea...

SA Transcripts on Seeking Alpha | May 14, 2023

Acumen Pharmaceuticals Reports First Quarter 2023 Financial Results and Business Highlights

Expect to report topline results from INTERCEPT-AD, a Phase 1 clinical trial of ACU193 in patients with early Alzheimer’s disease, in the third quarter of 2023Cash, cash equivalents and marketable securities of $183.8 million as of March 31, 2023 expected to be sufficient to support clinical and operational activities through 2025Company to host conference call and webcast today at 8:00 a.m. ET CHARLOTTESVILLE, Va. and Carmel, Ind., May 09, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (

Yahoo | May 9, 2023

Acumen Pharmaceuticals to Participate in 2023 Bank of America Healthcare Conference

CHARLOTTESVILLE, Va. and CARMEL, Ind., May 04, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in a fireside chat at the 2023 Bank of America Healthcare Conference on Thursday, May 11, 2023 at 8:00 a.m. PT (11:00 a.m. ET). The live webcast may be accessed under t

Yahoo | May 4, 2023

Acumen Pharmaceuticals to Report First Quarter Financial Results on May 9, 2023

CHARLOTTESVILLE, Va. and CARMEL, Ind., May 02, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS) (“Acumen” or the “Company”), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers (AβOs) for the treatment of Alzheimer’s disease, today announced that the Company will report first quarter financial results on Tuesday, May 9, 2023. The Company will host a conference call and live audio webcast at 8:00 a.m. ET t

Yahoo | May 2, 2023

Institutions own 26% of Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) shares but private equity firms control 42% of the company

Key Insights Acumen Pharmaceuticals' significant private equity firms ownership suggests that the key decisions are...

Yahoo | April 9, 2023

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q4 2022 Earnings Call Transcript

Acumen Pharmaceuticals, Inc. (NASDAQ:ABOS) Q4 2022 Earnings Call Transcript March 27, 2023 Operator: Thank you for standing by. Welcome to Acumen Pharmaceuticals Full Year 2022 Conference Call and Webcast. At this time, all participants are in a listen-only mode. After the speakers’ presentation, there will be a question-and-answer session. Please be advised that today’s conference […]

Yahoo | March 29, 2023

Acumen Pharmaceuticals Presents in vitro Human Neuron Model for Evaluating Binding of Amyloid Beta Oligomers in Alzheimer’s Disease

Data describe induced pluripotent stem cell (iPSC)-derived excitatory neurons as a human model for assessing selectivity of drug binding to soluble amyloid beta oligomers in Alzheimer’s diseaseResults provide evidence that oligomer size may influence neuronal binding and detection, and substantiate the importance of oligomer preparation and antibody selection in assay resultsPoster presented at AD/PD 2023, the International Conference on Alzheimer’s and Parkinson’s Diseases and related neurologi

Yahoo | March 28, 2023

Acumen Pharmaceuticals Reports Financial Results for Full Year Ended December 31, 2022 and Business Highlights

INTERCEPT-AD, a Phase 1 clinical trial of ACU193 in patients with early Alzheimer’s disease, completed enrollment in February 2023 Topline data expected in the third quarter of 2023 Cash, cash equivalents and marketable securities of $193.4 million as of Dec. 31, 2022 expected to be sufficient to support clinical and operational goals through 2025Company to host conference call and webcast today at 8:00 a.m. ET CHARLOTTESVILLE, Va. and CARMEL, Ind., March 27, 2023 (GLOBE NEWSWIRE) -- Acumen Phar

Yahoo | March 27, 2023

Acumen Pharmaceuticals to Participate in Stifel 2023 Virtual CNS Days

CHARLOTTESVILLE, Va. and CARMEL, Ind., March 22, 2023 (GLOBE NEWSWIRE) -- Acumen Pharmaceuticals, Inc. (NASDAQ: ABOS), a clinical-stage biopharmaceutical company developing a novel therapeutic that targets toxic soluble amyloid beta oligomers for the treatment of Alzheimer’s disease, announced today that management will participate in a fireside chat at the Stifel 2023 Virtual CNS Days on Wednesday, March 29, 2023 at 12:30 p.m. ET. The live webcast may be accessed under the Investors tab on www.

Yahoo | March 22, 2023